ORBIMED ADVISORS LLC 13D and 13G filings for Mereo BioPharma Group plc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 6:51 pm Sale | 2023-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 0 0.000% | -10,378,591 (Position Closed) | Filing |
| 2023-02-14 4:40 pm Purchase | 2022-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 10,378,591 5.920% | 4,315,246 (+71.17%) | Filing |
| 2022-02-11 4:31 pm Purchase | 2021-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 6,063,345 5.590% | 1,544,989 (+34.19%) | Filing |
| 2021-02-12 5:00 pm Purchase | 2020-12-31 | 13G | Mereo BioPharma Group plc MREO | ORBIMED ADVISORS LLC | 4,518,356 6.660% | 4,518,356 (New Position) | Filing |